UY39687A - MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF - Google Patents

MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF

Info

Publication number
UY39687A
UY39687A UY0001039687A UY39687A UY39687A UY 39687 A UY39687 A UY 39687A UY 0001039687 A UY0001039687 A UY 0001039687A UY 39687 A UY39687 A UY 39687A UY 39687 A UY39687 A UY 39687A
Authority
UY
Uruguay
Prior art keywords
antigen
binding fragment
specifically binds
monoclonal antibody
ganglioside
Prior art date
Application number
UY0001039687A
Other languages
Spanish (es)
Inventor
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Sergei Andreevich Ageev
Yulia Sergeevna Chernykh
Diana Aleksandrovna Kondinskaia
Valeriia Evgenevna Shigina
Dina Khaidarovna Sakharova
Mariia Anatolevna Grefenshtein
Alina Konstantinovna Stolyarova
Valery Vladimirovich Solovyev
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021107773A external-priority patent/RU2796937C2/en
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39687A publication Critical patent/UY39687A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere al campo de la biotecnología, en particular a un anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al GD2. La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades mediados por GD2, usos de los anticuerpos para tratar enfermedades mediados por GD2.The present invention relates to the field of biotechnology, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to GD2. The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing them, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods of treating GD2-mediated diseases, uses of the antibodies to treat GD2-mediated diseases.

UY0001039687A 2021-03-24 2022-03-24 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF UY39687A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021107773A RU2796937C2 (en) 2021-03-24 Monoclonal antibody or its antigen-binding fragment which specifically binds to gd2 (gd2 ganglioside) and its use

Publications (1)

Publication Number Publication Date
UY39687A true UY39687A (en) 2022-08-31

Family

ID=83395963

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039687A UY39687A (en) 2021-03-24 2022-03-24 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF

Country Status (9)

Country Link
CN (1) CN117677695A (en)
AR (1) AR125219A1 (en)
CL (1) CL2023002843A1 (en)
CO (1) CO2023012549A2 (en)
CR (1) CR20230456A (en)
EC (1) ECSP23072412A (en)
TW (1) TW202304989A (en)
UY (1) UY39687A (en)
WO (1) WO2022203552A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1706428T3 (en) * 2004-01-22 2010-02-26 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
KR101834026B1 (en) * 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 Anti-gd2 antibodies
EP2968545B1 (en) * 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies

Also Published As

Publication number Publication date
CO2023012549A2 (en) 2023-10-09
WO2022203552A1 (en) 2022-09-29
CL2023002843A1 (en) 2024-03-22
CR20230456A (en) 2023-12-13
AR125219A1 (en) 2023-06-28
CN117677695A (en) 2024-03-08
ECSP23072412A (en) 2023-10-31
TW202304989A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
CO2021006248A2 (en) Anti-nkg2a antibodies and their uses
BR112019008010A2 (en) isolated monoclonal antibody or immunologically active fragment thereof, isolated bispecific monoclonal antibody, pharmaceutical composition, method for treating a disease in a human subject in need thereof, fusion protein, cd47 gene encoded immunodominant epitope, and biological molecule
MX2020008795A (en) Anti-tigit antibodies and uses thereof.
AR126019A1 (en) ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
CL2021000517A1 (en) Labeled antibody and / or fragment thereof comprising a monoclonal antibody or a fragment thereof, which specifically binds human tau; nucleic acid that encodes it; vector; cell; method of producing antibody; and use of the same to inhibit the aggregation of tau, and associated diseases (divisional application no. 202001003)
BR112016013347A8 (en) anti-il-33 neutralizing human monoclonal antibody, pharmaceutical composition, cytokine expression inhibitor, epitope, nucleic acid molecule, vector, host cell, method of production and use thereof.
BR112015029953A2 (en) anti-tweakr antibodies and their uses
BR112022000371A2 (en) Claudin18 antibodies and cancer treatment methods
CL2021002792A1 (en) Monoclonal antibody that specifically binds to gitr
WO2021227307A8 (en) Anti-cd73 antibody and use thereof
BR112022012474A2 (en) ANTI-LILRB1 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THEM, USE OF SUCH ANTIBODY TO TREAT OR PREVENT CANCER, METHOD OF PREPARING SUCH ANTIBODY, NUCLEIC ACID MOLECULE AND RECOMBINANT CELL AND VECTOR.
BR112017027702A2 (en) Vascular Endothelial Growth Factor 2 Antireceptor Antibodies (vegfr2)
EA202092125A1 (en) ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION
BR112022000628A2 (en) Anti-Tigit antibodies and their application
CO2021007053A2 (en) Methods of Treating Graves' Ophthalmopathy Using Anti-fcrn Antibodies
BR112022025574A2 (en) ANTIBODIES THAT BINDS CD3, POLYNUCLEOTIDE ISOLATED, HOST CELL, METHOD FOR PRODUCING AN ANTIBODY THAT BINDS CD3 AND FOR TREAT A DISEASE IN AN INDIVIDUAL, PHARMACEUTICAL COMPOSITION, ANTIBODY FOR USE AND INVENTION
PE20211792A1 (en) MONOCLONAL ANTIBODIES THAT BIND SPECIFICALLY TO THE BETA REGION OF THE HUMAN T-CELL RECEPTOR FAMILY TRBV-9, AND METHODS FOR ITS USE
UY39687A (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS GD2 (GD2 GANGLIOSIDE), AND USE THEREOF
EA202092122A1 (en) ANTIBODIES AGAINST TIP-1 AND THEIR APPLICATION
AR127635A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF
BR112022025020A2 (en) DOSAGE OF POLIOMAVIRUS NEUTRALIZING ANTIBODIES
ECSP23097121A (en) Isolated bispecific antibody that specifically binds CD47 and PD-L1
AR117072A1 (en) ANTI-NKG2A ANTIBODIES AND USES OF THEM
BR112022020716A2 (en) ANTI-TUMOR ANTIBODIES ASSOCIATED WITH ANTIGEN AND THEIR USES